| Symbol | BOLD |
|---|---|
| Name | BOUNDLESS BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9880 CAMPUS POINT DRIVE,SUITE 120, SAN DIEGO, California, 92121, United States |
| Telephone | (858) 766-9912 |
| Fax | — |
| — | |
| Website | https://www.boundlessbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001782303 |
| Description | Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. Additional info from NASDAQ: |
TANG KEVIN 🟢 acquired 4.9K shares of Boundless Bio, Inc. (BOLD) at $2.44 Transaction Date: Jul 17, 2026 | Filing ID: 000017
Read moreTANG KEVIN 🟢 acquired 64.0K shares of Boundless Bio, Inc. (BOLD) at $2.44 Transaction Date: Jul 14, 2026 | Filing ID: 000015
Read moreCRANDELL KEITH 🟡 adjusted position in 16.0K shares (1 derivative) of Boundless Bio, Inc. (BOLD) at $2.49 Transaction Date: Jul 01, 2026 | Filing ID: 000622
Read moreARCH Venture Fund IX, L.P. 🟡 adjusted position in 16.0K shares (1 derivative) of Boundless Bio, Inc. (BOLD) at $2.49 Transaction Date: Jul 01, 2026 | Filing ID: 000621
Read moreTANG KEVIN 🟢 acquired 107.5K shares of Boundless Bio, Inc. (BOLD) at $2.54 Transaction Date: Jun 30, 2026 | Filing ID: 000009
Read moreTANG KEVIN 🟢 acquired 286.3K shares of Boundless Bio, Inc. (BOLD) at $2.56 Transaction Date: Jun 25, 2026 | Filing ID: 000008
Read moreNew Form SCHEDULE 13G - Boundless Bio, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001214659-26-007864 <b>Size:</b> 27 KB
Read moreNew Form 3 - Boundless Bio, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001178579-26-000007 <b>Size:</b> 6 KB
Read more$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)
Read moreBOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07408089 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced … | Phase1 | Breast Cancer | Recruiting | 2026-02-25 | 2029-05-31 | ClinicalTrials.gov |
| NCT06299761 | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene… | Phase1 | Solid Tumor | Terminated | 2024-03-28 | 2025-06-25 | ClinicalTrials.gov |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the… | Phase1 | Triple Negative Breast Cancer (TNBC) | Terminated | 2023-03-24 | 2026-03-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| BBI-825 | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT06299761 |
| BBI-825 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | TERMINATED | NCT05827614 |
| Futibatinib | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | TERMINATED | NCT05827614 |
| Erlotinib | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | TERMINATED | NCT05827614 |
| BBI-355 | Other | Phase PHASE1 | Triple Negative Breast Cancer (TNBC) | TERMINATED | NCT05827614 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT07408089 |
| BBI-940 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT07408089 |
| BBI-825 | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT06299761 |